Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.41 |
| ▸ | HTR2C | P28335 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 5/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30498325 | 1.00 | HTR2A (0.41) | HTR2AHTR2CALDH1A1HSD17B10HTT | |
| SCHEMBL31359665 | 0.90 | HTR2A (0.40) | HTR2AHTR2CALDH1A1HSD17B10HTT | |
| SCHEMBL25271978 | 0.84 | HTR2C (0.44) | HTR2AHTR2CALDH1A1HSD17B10HTT | |
| SCHEMBL25753129 | 0.83 | HTR2A (0.36) | HTR2AHTR2CALDH1A1HSD17B10HTT | |
| SCHEMBL25753193 | 0.82 | HTR2C (0.49) | HTR2AHTR2CALDH1A1HSD17B10HTT | |
| SCHEMBL25758418 | 0.81 | MAP3K12 (0.35) | HTR2AHTR2CALDH1A1HSD17B10HTT | |
| SCHEMBL30498058 | 0.81 | MAP3K12 (0.35) | HTR2AHTR2CALDH1A1HSD17B10HTT | |
| SCHEMBL27199681 | 0.80 | HSD17B10 (0.42) | HTR2AHTR2CALDH1A1HSD17B10HTT | |
| Hydrochloric Acid SCHEMBL25289529 | 0.80 | HTR2A (0.41) | HTR2AHTR2CALDH1A1HSD17B10HTT | |
| SCHEMBL30498270 | 0.79 | HTR2A (0.40) | HTR2AHTR2CALDH1A1HSD17B10HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-10-29 | — | — | US | disclosed |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| WO-2023109954-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | HTR2A 3276/4885HTR2C 3809/4885ALDH1A1 4805/4885 |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | HTR2A 3276/4885HTR2C 3809/4885ALDH1A1 4805/4885 |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | TYK2, JAK2, JAK1 | HTR2A 3276/4885HTR2C 3809/4885ALDH1A1 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.